이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

GLP-1/GIP 수용체 작용제를 사용하는 환자에서 탈모 치료용 음용형 뉴트라슈티컬의 유효성 및 안전성

2026년 10월 1일 업데이트: Olistic Research Labs S.L.

GLP-1/GIP 수용체 작용제 치료 환자에서 탈모 개선을 위한 음용형 뉴트라슈티컬의 유효성 및 안전성 평가: 이중맹검, 1:1 무작위 배정, 위약 대조 연구.

The purpose of this clinical trial is to evaluate the efficacy of Olistic© Next Women, a nutraceutical supplement, compared with placebo in improving hair loss in patients undergoing treatment with GLP-1/GIP agonists. This 6-month, randomized, placebo-controlled clinical study investigates whether daily supplementation with Olistic© Next Women leads to significant improvements in hair loss in this patient population. In addition, the study assesses the safety and tolerability of the product throughout the treatment period.

연구 개요

상태

모병

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

40

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Madrid
      • Madrid, Madrid, 스페인, 28006
        • 모병
        • Grupo Dermatologico Y Estetico Pedro Jaen S.A.
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

35년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

설명

Inclusion Criteria:

  • Female gender.
  • Age >35 years.
  • Initiation of treatment with a GLP-1/GIP agonist, or treatment duration < 3 months, as per routine clinical practice in the endocrinology clinic.
  • Having signed the participant information sheet and the written informed consent and having been informed of the objective of the study.
  • Additional criteria to be included by the client.

Exclusion Criteria:

  • Allergy or hypersensitivity to any of the components of the product, or to a product from a similar category to the one being tested.
  • Scalp diseases: cicatricial alopecia, alopecia areata, folliculitis decalvans, psoriasis, moderate to severe seborrheic dermatitis, eczema, cancer, etc.
  • Women presenting alopecia due to an underlying medical condition (hypothyroidism, anemia, lupus, etc.).
  • Pharmacological treatment that may promote the onset of telogen effluvium, initiated within the 3 months prior to study start (e.g., valproic acid, carbamazepine, phenytoin, selective serotonin reuptake inhibitors, oral anticoagulants, retinoids, beta-blockers). Patients who have undergone a dose change of these medications within the same period are also excluded.
  • Women with uncontrolled thyroid disorders (hyperthyroidism or hypothyroidism) within the 6 months prior to study initiation.
  • Women who have used anti-hair loss products within the last 3 months.
  • Women who have initiated or undergone dermatological treatment for hair loss within the last 6 months (minoxidil, finasteride, PRP, mesotherapy, etc.).
  • Women who have undergone hair transplantation within the 18 months prior to study initiation.
  • Women who have initiated treatment with anxiolytics, antidepressants, amphetamines, ACE inhibitors, or iron within the last 3 months.
  • Women who initiated or discontinued hormonal treatment (oral contraceptives, oral or topical hormone replacement therapy, ovarian stimulation) within the 3 months prior to study initiation.
  • Pregnant women, postpartum women (within 6 months), breastfeeding women, or women planning to become pregnant during the study period.
  • Additional exclusion criteria to be specified by the sponsor.
  • Any condition that, in the investigator's opinion, makes participation in the study inappropriate.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 지지 요법
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
위약 비교기: 위약군

Drinkable formulation consisting of an excipient formulation designed to mimic the organoleptic properties of the active product, reproducing its color and texture while achieving a highly similar taste profile.

실험적: 활성 제품 군

Drinkable multifactorial food supplement in liquid form, administered once daily in a 25 mL single-dose vial, for a duration of 180 days. The formulation contains a combination of vitamins, minerals, amino acids, plant extracts, and other bioactive compounds designed to support hair growth and scalp health in women +45.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Hair loss
기간: From baseline to Day 180.

• Patient Reported Outcome using the Hair Shedding Scale: will assess the degree of hair loss among participants. On the day of the visit, they will be shown an A4 sheet with six ranges: between 1 (minimal shedding) to 6 (copious hair shedding).

Ref. Perera E and Sinclair R, 2017

From baseline to Day 180.

2차 결과 측정

결과 측정
측정값 설명
기간
Hair loss
기간: From baseline to Day 180.

Comb and Wash Test: this test will quantify the number of fallen hairs (outcome number of shed hairs). It will be carried out after refraining from washing the hair for 48 hours and combing the hair for 24 hours.

From baseline to Day 180.
Body composition
기간: From baseline to Day 180.

Body weight (Kg). Using bioelectrical impedance analysis (BIA) with the Tanita MC-780MA body composition monitor

From baseline to Day 180.
Body composition
기간: From baseline to Day 180.

BMI (Kg/m2). Using bioelectrical impedance analysis (BIA) with the Tanita MC-780MA body composition monitor

From baseline to Day 180.
Body composition
기간: From baseline to Day 180.

Fat mass and fat-free mass percentages. Using bioelectrical impedance analysis (BIA) with the Tanita MC-780MA body composition monitor

From baseline to Day 180.
Serum iron level
기간: From baseline to Day 180.

Serum iron concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Ferritin level
기간: From baseline to Day 180.

Serum ferritin concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Transferrin level
기간: From baseline to Day 180.

Serum transferrin concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Transferrin saturation
기간: From baseline to Day 180.

Transferrin saturation percentage calculated from iron metabolism parameters obtained from blood samples.

From baseline to Day 180.
Serum zinc level
기간: From baseline to Day 180.

Serum zinc concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
25-hydroxyvitamin D level
기간: From baseline to Day 180.

Serum 25-hydroxyvitamin D concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Serum folate level
기간: From baseline to Day 180.

Serum folate concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Vitamin B12 level
기간: From baseline to Day 180.

Serum vitamin B12 concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Serum albumin level
기간: From baseline to Day 180.

Serum albumin concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Thyroid-stimulating hormone (TSH) level
기간: From baseline to Day 180.

Serum thyroid-stimulating hormone concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Free thyroxine (free T4) level
기간: From baseline to Day 180.

Serum free thyroxine concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Total testosterone level
기간: From baseline to Day 180.

Serum total testosterone concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Free testosterone level
기간: From baseline to Day 180.

Serum free testosterone concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Dehydroepiandrosterone sulfate (DHEA-S) level
기간: From baseline to Day 180.

Serum dehydroepiandrosterone sulfate concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Sex hormone-binding globulin (SHBG) level
기간: From baseline to Day 180.

Serum sex hormone-binding globulin concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Fasting glucose level
기간: From baseline to Day 180.

Fasting blood glucose concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Glycated hemoglobin (HbA1c)
기간: From baseline to Day 180.

Glycated hemoglobin measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Fasting insulin level
기간: From baseline to Day 180.

Fasting serum insulin concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
HOMA-IR
기간: From baseline to Day 180.

Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) calculated from fasting glucose and fasting insulin values.

From baseline to Day 180.
Total cholesterol level
기간: From baseline to Day 180.

Total cholesterol concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
HDL cholesterol level
기간: From baseline to Day 180.

HDL cholesterol concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
LDL cholesterol level
기간: From baseline to Day 180.

LDL cholesterol concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Triglyceride level
기간: From baseline to Day 180.

Serum triglyceride concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Aspartate aminotransferase (AST) level
기간: From baseline to Day 180.

AST concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Alanine aminotransferase (ALT) level
기간: From baseline to Day 180.

ALT concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Gamma-glutamyl transferase (GGT) level
기간: From baseline to Day 180.

GGT concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Blood urea level
기간: From baseline to Day 180.

Blood urea concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.
Serum creatinine level
기간: From baseline to Day 180.

Serum creatinine concentration measured in blood samples using standard clinical laboratory methods.

From baseline to Day 180.

기타 결과 측정

결과 측정
측정값 설명
기간
Self-assessment questionnaire
기간: From baseline to Day 180.

Subject-reported perception of hair condition assessed using a 12-item questionnaire covering perceived hair density, hair shedding, hair strength, hair volume, appearance, and scalp condition. Each item is rated on a 5-point Likert scale ranging from "strongly disagree" to "strongly agree." Higher scores indicate greater perceived improvement in hair and scalp condition.

From baseline to Day 180.
Food consumption frequency questionnaire (PREDIMED questionnaire)
기간: From baseline to Day 180.

Adherence to the Mediterranean diet assessed using the validated 14-item PREDIMED (Prevención con Dieta Mediterránea) questionnaire. The questionnaire evaluates the frequency of consumption of key food groups and dietary habits characteristic of the Mediterranean diet, including olive oil use, fruit and vegetable intake, legumes, fish, nuts, red meat, sugary beverages, commercial pastries, and wine consumption. Each item is scored 0 or 1, resulting in a total score ranging from 0 to 14, with higher scores indicating greater adherence to the Mediterranean diet.

From baseline to Day 180.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 3월 16일

기본 완료 (추정된)

2027년 5월 31일

연구 완료 (추정된)

2027년 8월 31일

연구 등록 날짜

최초 제출

2026년 3월 9일

QC 기준을 충족하는 최초 제출

2026년 3월 17일

처음 게시됨 (실제)

2026년 3월 19일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 1일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • CT-ON-04

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .